Two new studies revealed the prevalence of pathogenic variants in breast cancer-related genes, while highlighting genes that may be most informative in the clinic.
The firm expects to receive a CE mark later this year for its RT-qPCR breast cancer recurrence assay, which characterizes epithelial CTCs by detecting cytokeratin-19 expression.
The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.
Hologic said that Biotheranostics' PCR-based gene expression tests have been validated in large studies in areas of oncology with high growth potential.
FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.
A meta-analysis showed that early circulating tumor cell dynamics were associated with overall survival using Menarini Silicon Biosystems' CellSearch assay.
The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.
The results, presented at SABCS this week, leave open whether the added benefit from chemo seen in premenopausal women may be due to chemo-induced hormone reduction.
